Table 4 Alterations in biomarker parameters induced by chemotherapy in breast cancer patients developing VTE within 3 months of chemotherapy

From: Early changes in the haemostatic and procoagulant systems after chemotherapy for breast cancer

Coagulation marker Prechemotherapy (n) Day 1 (post-chemotherapy) (n) Day 4 (post-chemotherapy) (n) Day 8 (post-chemotherapy) (n) 3 months (post-chemotherapy) (n)
APTT secs, mean (CI) 22.2 (18.7–25.6) (9) 19.8 (18.2–21.3) (9) 21.1 (19.4–22.7) (11) 21.6 (19.4–23.7) (8) 21.0 (18.6–23.4) (9)
PT secs, mean (CI) 11.5 (11.0–12.0) (9) 11.9 (11.5–12.4) (11) 11.9 (11.4–12.4) (11) 12.1 (11.3–12.9) (9) 11.8 (10.9–12.6) (7)
TAT μg ml−1, geometric mean (CI) 8.9 (2.4–32.5) (8) 28.6 (4.9–167.1) (8) 6.3 (2.4–16.4) (8) 5.2 (2.4–11.1) (8) 3.9 (2.5–5.9) (7)
Fibrinogen g l−1 mean(CI) 4.9 (3.0–6.9) (7) 4.2 (2.5–5.9) (8) 4.2 (2.9–5.5) (10) 4.4 (3.0–5.7) (7) 5.6 (4.5–6.8) (8)
D-dimer ng ml−1, geometric mean (CI) 1618.6 (979.0–2676.1) (12) 1653.1 (996.0–2743.8) (11) 1297.1 (585.2–2875.1) (11) 1301.9 (642.4–2638.6) (11) 966.7 (504.9–1850.8) (9)
Platelet count × 109 l−1 mean (CI) 342.5 (265.8–419.2) (12) 338.9 (246.4–431.4) (10) 269.6 (225.5–313.8) (11) 274.0 (216.8–331.2) (11) 386.2 (238.3–534.1) (10)
TF μg ml−1, geometric mean (CI) 231.1 (104.1–513.2) (11) 228.7 (107.1–488.5) (10) 190.9 (96.9–376.4) (10) 192.9 (82.2–452.5) (10) 81.4 (22.9–289.5) (8)
CP mU, geometric mean (CI) 31.4 (26.6–37.1) (11) 35.7 (28.4–44.9) (11) 32.5 (26.3–40.1) (11) 28.2 (22.9–34.7) (11) 27.8 (21.2–36.5) (9)
pVEGF μg ml−1, geometric mean (CI) 27.8 (14.3–54.1) (12) 19.5 (10.4–36.6) (11) 19.0 (9.4–38.3) (11) 23.4 (13.2–41.5) (11) 18.7 (13.7–25.5) (9)